Eli Lilly and Company (NYSE: LLY) will participate in TD Cowen's 45th Annual Health Care Conference on March 4, 2025. Jake ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where Eli ...

Eli Lilly and Company's latest 10-K report for the year ended December 31, 2024, reveals significant financial growth. The company reported a revenue of $45,042.7 million, marking a 32% increase from ...

Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today ...

In the final days of 2024, three pharmaceutical giants sued the federal government. In their joint lawsuit, Amgen, Eli Lilly ...

It is tailored to patients being treated with Lilly's oncology drugs – which include blockbuster CDK 4/ 6 inhibitor Verzenio (abemaciclib) for hormone receptor-positive, HER2-negative breast ...

Eli Lilly now has a second approved drug from its takeover of Loxo Oncology last year after getting the go-ahead from the FDA for RET inhibitor Retevmo. The US regulator says Retevmo ...

Aristotle Atlantic’s Focus Growth Composite posted a total return of 5.05% gross of fees, underperforming the 7.07% total return of the Russell 1000 Growth Index.